GAA

Genepharm (GAA) Shares Recommendation


ABN Amro have upgrapded their rating for the Genepharm (GAA) stock from Hold to a Buy recommendation and a valuation of $1.32 per share. The broker have noted that the company's acquisition of Douglas Pharmaceuticals will speed its entry into Australia's generic drug market, where the company is poised to become the third largest player.

Syndicate content

Recommended Websites